TBG Diagnostics logo

TDL - TBG Diagnostics Share Price

A$0.27 0.0  0.0%

Last Trade - 17/03/20

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £1.89m
Position in Universe th / 1833
Unlock TDL Revenue
Relative Strength (%)
1m +1,105%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.81 3.27 1.39 4.60 3.24 3.44 128 108.7 +33.7%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, TBG Diagnostics Ltd revenues increased 6% to A$3.4M. Net loss before extraordinary items increased from A$2.3M to A$11.1M. Revenues reflect Revenue From Continuing Operations increase of 6% to A$3.3M, Interest Revenue increase of 35% to A$98K. Higher net loss reflects Foreign Exchange Gain decrease of 44% to A$63K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


TDL Revenue Unlock TDL Revenue

Net Income

TDL Net Income Unlock TDL Revenue

Normalised EPS

TDL Normalised EPS Unlock TDL Revenue

PE Ratio Range

TDL PE Ratio Range Unlock TDL Revenue

Dividend Yield Range

TDL Dividend Yield Range Unlock TDL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
TDL EPS Forecasts Unlock TDL Revenue
Profile Summary

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated September 26, 1989
Public Since December 22, 1995
No. of Shareholders: n/a
No. of Employees: 41
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 217,587,289
Free Float (0.0%)
Eligible for
TDL Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TDL
Upcoming Events for TDL
Saturday 29th August, 2020 Estimate
Half Year 2020 TBG Diagnostics Ltd Earnings Release
Frequently Asked Questions for TBG Diagnostics
What is the TBG Diagnostics share price?

As of 17/03/20, shares in TBG Diagnostics are trading at A$0.27, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the TBG Diagnostics share price performed this year?

Shares in TBG Diagnostics are currently trading at A$0.27 and the price has moved by 0.592k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the TBG Diagnostics price has moved by 0.648k% over the past year.

What are the analyst and broker recommendations for TBG Diagnostics?

There are no analysts currently covering TBG Diagnostics.

When will TBG Diagnostics next release its financial results?

TBG Diagnostics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the TBG Diagnostics dividend yield?

TBG Diagnostics does not currently pay a dividend.

Does TBG Diagnostics pay a dividend?

TBG Diagnostics does not currently pay a dividend.

When does TBG Diagnostics next pay dividends?

TBG Diagnostics does not currently pay a dividend.

How do I buy TBG Diagnostics shares?

To buy shares in TBG Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of TBG Diagnostics?

Shares in TBG Diagnostics are currently trading at A$0.27, giving the company a market capitalisation of £n/a.

Where are TBG Diagnostics shares listed? Where are TBG Diagnostics shares listed?

Here are the trading details for TBG Diagnostics:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: TDL
What kind of share is TBG Diagnostics?

We were not able to load our ranking data for TBG Diagnostics

Is there a TBG Diagnostics share price forecast 2020?

We were not able to load any forecast data for TBG Diagnostics.

How can I tell whether the TBG Diagnostics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TBG Diagnostics. Over the past six months, the relative strength of its shares against the market has been 0.941k%. At the current price of A$0.27, shares in TBG Diagnostics are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the TBG Diagnostics PE Ratio?

We were not able to find PE ratio data for TBG Diagnostics.

Who are the key directors of TBG Diagnostics?

TBG Diagnostics's management team is headed by:

Shi-Chung Chang - NED
Lee Horobin - GMG
Fleur Lankesheer - OTH
Leslie Tillack - CEX
Indrajit Arulampalam - CHM
Keith Dredge - OTH
Emily Lee - NED
Eugene Cheng - NED
Justyn Stedwell - SEC
Wang Hsi-Kai - DRC
Willy Hsu - COO
Who are the major shareholders of TBG Diagnostics?

Here are the top five shareholders of TBG Diagnostics based on the size of their shareholding:

Medigen Biotechnology Corp Corporation
Percentage owned: 48.68% (105.9m shares)
Eternal Materials Co Ltd Corporation
Percentage owned: 18.48% (40.2m shares)
Wang (Fu Mei) Individual Investor
Percentage owned: 0.99% (2.16m shares)
Lu (Yung Fong) Individual Investor
Percentage owned: 0.72% (1.57m shares)
Wang (Wen Ming) Individual Investor
Percentage owned: 0.72% (1.58m shares)
Similar to TDL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.